Search results

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago. These

Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the

Shares of Denali Therapeutics, Inc. DNLI have gained 33.1% in the last three months compared with the industry’s growth of 7.4%. The stock has outperformed the sector and the S&P 500 Index during